RT Journal Article
SR Electronic
T1 Comparison of initial drug treatment of incident COPD patients with German treatment guidelines
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA2406
DO 10.1183/13993003.congress-2021.PA2406
VO 58
IS suppl 65
A1 Claus F Vogelmeier
A1 Marlene Hechtner
A1 Nils Picker
A1 Angela Neitz
A1 Patrick Hofmann
A1 Ulf Maywald
A1 Thomas Wilke
A1 Roland Buhl
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA2406.abstract
AB Introduction: The current German COPD guidelines recommends a treatment escalation procedure. Initial treatment should generally not include use of ICS.Aims and objectives: This claims data analysis aims to find out whether real-world first-line treatment of newly diagnosed COPD patients in Germany was in line with national 2018 COPD guideline recommendations.Methods: Claims data from incident COPD patients were analyzed retrospectively from 04/2014-03/2019. Continuously insured non-asthmatic patients ≥ 40 years, who had received ≥ 2 outpatient specialist’s diagnoses and/or ≥ 1 inpatient COPD diagnosis with 12-month follow-up were included.Patients not treated in line with 2018 German treatment guidelines were determined by the percentage of patients with any ICS therapy within 4 weeks after initial diagnosis as well as the percentage of patients with LAMA/LABA/ICS prescription but ≤ 1 outpatient diagnosis and no inpatient diagnosis of an exacerbation (ICD-10 J44.1) at the first date of the LAMA/LABA/ICS prescription.Results: Data were analyzed from 14,213 patients with newly diagnosed COPD (mean age: 70.1, females: 41.2%). 14.1% (n=2,008) of the patients received an ICS-containing therapy within 4 weeks after the initial diagnosis. 1,019 incident patients were prescribed a LAMA/LABA/ICS therapy within 12 months after diagnosis, of these, 68.9% (n=702) patients had ≤ 1 outpatient diagnosis and no inpatient diagnosis of an exacerbation.Conclusion: The majority of initial prescriptions for newly diagnosed COPD patients were in line with current COPD guideline recommendations, however the use of triple therapy was not consistent with COPD patient exacerbation risk.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2406.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).